SIP
ZVRA icon

Stoneridge Investment Partners’s Zevra Therapeutics ZVRA Stock Holding History

Stoneridge Investment Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$306K Hold
32,788
– – 0.22% 85
2025
Q4 		$294K Buy
32,788
+11,659
+55% +$110K 0.2% 86
2025
Q3 		$201K Buy
+21,129
New +$212K 0.14% 97

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Stoneridge Investment Partners's ZVRA Position: Q1 2026 in Review

Stoneridge Investment Partners held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 32,788 shares worth $306K. The position accounts for 0.22% of the portfolio, ranked #85.

Stoneridge Investment Partners first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Stoneridge Investment Partners held 32,788 shares of Zevra Therapeutics worth $306K as of Q1 2026.
  • Stoneridge Investment Partners left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up 0.22% of Stoneridge Investment Partners's portfolio in Q1 2026, its #85 holding.
  • Stoneridge Investment Partners first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Stoneridge Investment Partners's 13F filing for Q1 2026, filed 6 May 2026.